App is temporarily unavailable

服藥小幫手: 用藥提醒

協助養成固定用藥習慣,讓治療成為日常生活的一部分

Published by: Novo Nordisk

Description

服藥小幫手應用程式適用於使用口服Semaglutide的第二型糖尿病病人。
提醒您每日按時服用口服 Semaglutide建立新的常規,並以良好的方式開始治療 2 型糖尿病。 每天早上,您都會收到一條通知,幫助您建立自己關於服用口服 Semaglutide的良好習慣。
該應用程式的功能:
• 提醒您每天服用口服 Semaglutide
• 教導正確的服藥方式以獲得最佳治療效果
• 輕鬆獲取有關口服 Semaglutide的信息
• 記錄您今天是否服藥
該應用程式將為您提供用藥的提醒和指導,是幫助您在使用口服 Semaglutide治療初期時,可以快速上手的實用型應用程式!
經過30 天後,例行程序已成為您早上日常常態的一部分,您通常不再需要該應用程式。
如果您的醫師已為您處方口服 Semaglutide,請立即下載服藥小幫手App。
Hide Show More...

服藥小幫手: 用藥提醒 FAQ

  • Is 服藥小幫手: 用藥提醒 free?

    Yes, 服藥小幫手: 用藥提醒 is completely free and it doesn't have any in-app purchases or subscriptions.

  • Is 服藥小幫手: 用藥提醒 legit?

    Not enough reviews to make a reliable assessment. The app needs more user feedback.

    Thanks for the vote

  • How much does 服藥小幫手: 用藥提醒 cost?

    服藥小幫手: 用藥提醒 is free.

  • What is 服藥小幫手: 用藥提醒 revenue?

    To get estimated revenue of 服藥小幫手: 用藥提醒 app and other AppStore insights you can sign up to AppTail Mobile Analytics Platform.

User Rating

5 out of 5

23 ratings in Taiwan

5 star
23
4 star
0
3 star
0
2 star
0
1 star
0
Ratings History

服藥小幫手: 用藥提醒 Reviews

App doesn't have any reviews yet

服藥小幫手: 用藥提醒 Installs

Last 30 days

服藥小幫手: 用藥提醒 Revenue

Last 30 days

服藥小幫手: 用藥提醒 Revenue and Downloads

Gain valuable insights into 服藥小幫手: 用藥提醒 performance with our analytics.
Sign up now to access downloads, revenue, and more.

App Info

Category
Medical
Publisher
Novo Nordisk
Languages
Danish, Hungarian, Hindi, Gujarati, Tamil, Bengali, Kannada, German, Panjabi, Oriya, French, Telugu, Swedish, Chinese, Italian, English, Dutch, Arabic, Assamese, Marathi, Malayalam
Recent release
1.8.7 (4 months ago )
Released on
Aug 13, 2020 (4 years ago )
Last Updated
1 month ago
This page includes copyrighted content from third parties, shared solely for commentary and research in accordance with fair use under applicable copyright laws. All trademarks, including product, service, and company names or logos, remain the property of their respective owners. Their use here falls under nominative fair use as outlined by trademark laws and does not suggest any affiliation with or endorsement by the trademark holders.